Login to Your Account



Epirus, Ranbaxy ink biosimilars deal for Asia, Africa


Wednesday, January 15, 2014

HONG KONG – Epirus Switzerland GmbH expanded its focus on emerging markets via a new licensing deal with India’s largest maker of generics and biosimilars.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription